SMMT$24.42
$24.0
Chart
Performance
Key Stats
AI SMMT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySummit Therapeutics Inc. shows significant long-term potential driven by its lead drug candidate, ivonescimab, and a strong performance in clinical trials. While currently not profitable and with high volatility, the potential market for its therapies, particularly in non-small cell lung cancer, is substantial. Investors should be aware of the inherent risks associated with biopharmaceutical development.
Thematic
Summit Therapeutics is positioned within the growing biopharmaceutical sector, specifically focusing on immunotherapy for cancer treatment. The development of ivonescimab, a bispecific antibody targeting PD-1 and angiogenesis, aligns with key trends in oncology drug development. However, the company's success is heavily dependent on the clinical trial outcomes and regulatory approvals.
Fundamental
Summit Therapeutics exhibits a strong balance sheet with substantial cash reserves, which is crucial for funding its ongoing clinical trials. However, the company is not yet generating revenue or profits, and its earnings per share are significantly negative. The valuation metrics are largely not applicable or indicate a very early stage of development.
Technical
The stock has shown strong upward momentum over the past year, significantly outperforming the broader market. However, recent technical indicators suggest a cooling-off period or potential for a short-term pullback, as some oscillators are in overbought territory. The stock is trading above key moving averages, indicating an overall positive trend.
| Factor | Score |
|---|---|
| Oncology Immunotherapy Market | 80 |
| Bispecific Antibody Development | 75 |
| Clinical Trial Progress | 70 |
| Regulatory Landscape | 65 |
| Biotechnology Sector Volatility | 50 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 10 |
| Revenue | 5 |
| Balance Sheet Health | 70 |
| Debt Level | 85 |
| Earnings Per Share (EPS) | 15 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 60 |
| Moving Averages | 80 |
| Volume Trends | 50 |
| Support and Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is negative (-113.5), which can be interpreted as an opportunity if the company is expected to return to profitability. This is common for growth-stage companies.
Significant Short-Term Gains
The stock has shown strong performance over various short-term periods, including 29.32% in one month and 50.25% year-to-date, indicating positive momentum.
Bearish Points (10)
Consistent Net Losses
The company has consistently reported net losses, with a significant net income of -$221.315 million in 2024Q4 and -$614.928 million in 2023Q4, raising concerns about profitability.
Zero Revenue
Reported revenue is zero for the periods 2024Q4, 2023Q4, 2022Q4, and 2021Q4, indicating the company is not generating sales from its core business operations.
Calendar
August 2025
7
Next Earnings Date
H: $-0.06
A: $-0.07
L: $-0.08
Profile
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Seasonals
Price Target
34.74 USD
The 39 analysts offering 1 year price forecasts for SMMT have a max estimate of 44.10 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in Non-Small Cell Lung Cancer (NSCLC) with its blockbuster immunotherapy Keytruda, setting the standard for SMMT's ivonescimab.
Weight: 90
Major competitor in NSCLC with Opdivo and a strong oncology pipeline; recently acquired Mirati Therapeutics, adding a targeted NSCLC therapy.
Weight: 88
Significant presence in NSCLC with approved drugs like Tagrisso (targeted therapy) and Imfinzi (immunotherapy), robust oncology R&D.
Weight: 85
Key player in global oncology and NSCLC with Tecentriq and a broad portfolio of cancer therapies, active in clinical development.